AstraZeneca Goes With Gracell to Gain an Edge in Next-Generation Cell Therapies
AstraZeneca is paying $1 billion up front to acquire Gracell Biotechnologies, a clinical-stage cell therapy developer. The deal is the latest in a series of AstraZeneca moves intended to expand its presence in the burgeoning cell therapy field.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed